Skip to main content
. Author manuscript; available in PMC: 2023 Nov 11.
Published in final edited form as: Sci Immunol. 2022 Nov 4;7(77):eabm7200. doi: 10.1126/sciimmunol.abm7200

Fig. 3. Thioredoxin restrains NLRP1 activation.

Fig. 3.

(A-D) N/TERT-1 keratinocytes were electroporated with control or TXN1 RNPs before being treated with VbP (10 μM) for 6 h or 16 h. Supernatants were analyzed for levels of LDH (A), IL-18 (B), and IL-1β (C) release, and both lysates and supernatants were subjected to immunoblotting analyses (D). (E,F) WT and NLRP1−/− N/TERT-1 keratinocytes were electroporated with control or TXN1 RNPs and treated with VbP (10 μM, 8 h). Supernatants were assessed for IL-1β release (E), and lysates and supernatants were evaluated by immunoblotting (F). Data in A-C and E are means ± SEM of three biological replicates. (G) Lysates from BMDMs from the indicated mouse strains were evaluated by immunoblotting. (H,I) The indicated mice were treated with vehicle or VbP (1 mg/kg, i.p.). The levels or serum cytokines were evaluated after 6 h by ELISA (H) or Luminex (I). Data in H are means ± SEM. Data in I are the column sum normalization of each cytokine (all data in Fig. S4D) depicted using Morpheus Software (Broad Institute). n = 8 and 11 for vehicle-treated WT and Txn1−/− mice, respectively, and n = 10 and 12 for VbP-treated WT and Txn1−/− mice, respectively. *p < 0.05, **p < 0.01,***p < 0.001 by two-sided Student’s t-test.